Cargando…
Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era
Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994685/ https://www.ncbi.nlm.nih.gov/pubmed/35419251 http://dx.doi.org/10.7759/cureus.23993 |
_version_ | 1784684158362058752 |
---|---|
author | Jennane, Selim Ababou, Mounir El Haddad, Mariyam Ait Sahel, Omar Mahtat, El Mehdi El Maaroufi, Hicham Doudouh, Abderrahim Doghmi, Kamal |
author_facet | Jennane, Selim Ababou, Mounir El Haddad, Mariyam Ait Sahel, Omar Mahtat, El Mehdi El Maaroufi, Hicham Doudouh, Abderrahim Doghmi, Kamal |
author_sort | Jennane, Selim |
collection | PubMed |
description | Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma and, on the other hand, to determine if positron emission tomography scan is a reliable means of early detection of this toxicity. Methods This is a retrospective study conducted in the clinical Hematology Department of Mohammed V Military Instruction Hospital, Rabat, Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin-based chemotherapy were included. The impact of different clinical and biological factors on the risk of bleomycin-induced lung toxicity occurrence was assessed using univariate and multivariate logistic regression. The benefit of positron emission tomography, usually performed as part of the re-assessment of Hodgkin’s lymphoma after two and four cycles, has been evaluated in the detection of bleomycin-induced lung toxicity. Results Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p = 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared to the escalated BEACOPPe regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) (p = 0.018) were statistically significant risk factors. After two and four courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms only in 36.4 % and 12.5% of patients, respectively. Conclusion Studies to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, two- and four-cycle positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity. |
format | Online Article Text |
id | pubmed-8994685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-89946852022-04-12 Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era Jennane, Selim Ababou, Mounir El Haddad, Mariyam Ait Sahel, Omar Mahtat, El Mehdi El Maaroufi, Hicham Doudouh, Abderrahim Doghmi, Kamal Cureus Oncology Introduction Bleomycin is a major antimitotic agent in the first-line treatment for Hodgkin's lymphoma. The main limitation of its use is its pulmonary toxicity. The objectives of this study are to find out the risk factors for the occurrence of bleomycin-induced lung toxicity in patients with Hodgkin's lymphoma and, on the other hand, to determine if positron emission tomography scan is a reliable means of early detection of this toxicity. Methods This is a retrospective study conducted in the clinical Hematology Department of Mohammed V Military Instruction Hospital, Rabat, Morocco. All patients with Hodgkin's lymphoma and treated with a bleomycin-based chemotherapy were included. The impact of different clinical and biological factors on the risk of bleomycin-induced lung toxicity occurrence was assessed using univariate and multivariate logistic regression. The benefit of positron emission tomography, usually performed as part of the re-assessment of Hodgkin’s lymphoma after two and four cycles, has been evaluated in the detection of bleomycin-induced lung toxicity. Results Among 124 patients included in the study, 18 (14.5%) patients experienced bleomycin-induced lung toxicity. On multivariate analysis, smoking (p = 0.038) and the use of the ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared to the escalated BEACOPPe regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) (p = 0.018) were statistically significant risk factors. After two and four courses of therapy, the positron emission tomography was able to predict the occurrence of bleomycin-induced lung toxicity before the appearance of clinical symptoms only in 36.4 % and 12.5% of patients, respectively. Conclusion Studies to identify risk factors for the development of bleomycin-induced lung toxicity are crucial to reduce toxicity in the treatment of Hodgkin's lymphoma. However, two- and four-cycle positron emission tomography scans cannot be considered as a reliable means of early detection of this toxicity. Cureus 2022-04-09 /pmc/articles/PMC8994685/ /pubmed/35419251 http://dx.doi.org/10.7759/cureus.23993 Text en Copyright © 2022, Jennane et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Jennane, Selim Ababou, Mounir El Haddad, Mariyam Ait Sahel, Omar Mahtat, El Mehdi El Maaroufi, Hicham Doudouh, Abderrahim Doghmi, Kamal Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title | Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title_full | Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title_fullStr | Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title_full_unstemmed | Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title_short | Bleomycin-Induced Lung Toxicity in Hodgkin's Lymphoma: Risk Factors in the Positron Emission Tomography Era |
title_sort | bleomycin-induced lung toxicity in hodgkin's lymphoma: risk factors in the positron emission tomography era |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994685/ https://www.ncbi.nlm.nih.gov/pubmed/35419251 http://dx.doi.org/10.7759/cureus.23993 |
work_keys_str_mv | AT jennaneselim bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT ababoumounir bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT elhaddadmariyam bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT aitsahelomar bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT mahtatelmehdi bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT elmaaroufihicham bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT doudouhabderrahim bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera AT doghmikamal bleomycininducedlungtoxicityinhodgkinslymphomariskfactorsinthepositronemissiontomographyera |